When Biogen acquired Nightstar Therapeutics in 2019 ... which was unable to meet its primary or secondary treatment objectives in the phase 3 STAR study of patients with choroideraemia, a rare ...

After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to look at ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including Skyclarys and Spinraza, rose 33% to $563 million in the quarter. Revenue rose 6% to ...